drugset
drugset / Trial / NCT01547728

Response of Recombinant Antithrombin in Heparin Resistant Patients Undergoing Cardiac Surgery

NCT01547728 ↗

Phase 4 Terminated 42 enrolled Mayo Clinic rEVO Biologics · collab
NaSingle-groupOpen-labelTreatment

Summary

The objective of this study is to prospectively evaluate the response of recombinant antithrombin (rAT) (ATRYN) in patients who are heparin resistant and are scheduled to undergo cardiac surgery.

Timeline

Start
2012-02
Primary completion
2014-02
Completion
2014-02

Drugs

EvaluationDrugModalityDoseRoute
Subject KW-3357 Protein / enzyme biologic 500 iu Intravenous

Indications

thrombophilia